Compounded semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist which may be used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m^2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
Sublingual administration takes a completely different route
Patients should consult their healthcare provider before regular use and should not exceed recommended dosages due to potential cardiac risks with misuse
Emerging research from around the world shows that the active ingredient in both, however, may be linked to sudden blindness
At 10 mg/mL : The top two rungs exceed a single 100-unit barrel, so at 12.5 and 15 mg the volume must be split across two injections or the vial reconstituted at a higher concentration with less water